KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Optimizing the Treatment of Experimental Autoimmune Encephalomyelitis via Pulmonary Delivery of Soluble Antigen Arrays

    Thumbnail
    View/Open
    Thati_ku_0099D_14563_DATA_1.pdf (8.593Mb)
    Issue Date
    2016-05-31
    Author
    Thati, Sharadvi
    Publisher
    University of Kansas
    Format
    116 pages
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Pharmaceutical Chemistry
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    Soluble antigen arrays (SAgAs) were used to treat experimental autoimmune encephalomyelitis (EAE), which is a mouse model for multiple sclerosis (MS). SAgAs offer a targeted therapy for MS, which is not present in current therapies. The different routes of administration, injection volume, dosing amount, and dosing schedule were explored to find that pulmonary instillation of SAgAs at 50 μL on a 200 nMol PLP basis on days 4, 7, and 10 of the study are most efficacious. With the next study, the different components of SAgAs (hyaluronic acid, PLP, LABL, and bifunctional peptide inhibitor) were also investigated via pulmonary delivery to find that PLP and SAgAs decreased the symptoms of EAE the most. PLP, HA-PLP, and SAgAs were further explored either via subcutaneous injection or pulmonary instillation to find that HA-PLP and SAgAs decreased disease progression in mice with EAE. Cytokine panels were also used to determine if tolerance was induced in these mice via the measurements of pro- and anti-inflammatory cytokines. Lastly, lung histology was explored to find signs of inflammation. Overall, SAgAs are found to be very efficacious in treating mice via PI and the presence of PLP makes a big difference. Other methods like the presence of regulatory T cells need to be used to find additional signs of tolerance induction in future studies.
    URI
    http://hdl.handle.net/1808/21656
    Collections
    • Pharmaceutical Chemistry Dissertations and Theses [141]
    • Dissertations [4473]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps